Pharmacokinetics of cefquinome in crucian carp (Carassius auratus gibelio) after oral, intramuscular, intraperitoneal, and bath administration

Pharmacokinetics of cefquinome in rainbow trout (Oncorhynchus mykiss) after intravascular, intraperitoneal, and oral administrations

This study aimed to determine the pharmacokinetics and bioavailability of cefquinome in rainbow trout (Oncorhynchus mykiss) following intravascular (IV), intraperitoneal (IP), and oral (PO) administrations at 14 ± 1°C. In this study, three hundred and six clinically healthy rainbow trout (110-140 g) were used. The fish received single IV, IP, and PO injections of cefquinome at 10 mg/kg dose. The plasma concentrations of cefquinome were measured using HPLC-UV and were evaluated using non-compartmental analysis. Cefquinome was measured up to 96 h for PO route and 144 h for IV and IP routes in plasma. Following IV administration, t_1/2ʎz , Cl_T , and V_dss were 18.85 h, 0.037 L/h/kg, and 0.84 L/kg, respectively. The C_max of IP and PO routes was 9.75 and 1.64 μg/ml, respectively. The bioavailability following IP and PO administrations was 59.46% and 12.33%, respectively. Cefquinome at 10 mg/kg dose may maintain T > MIC above 40% at 72 and 96 h intervals, respectively, following the IP and IV routes for bacteria with MIC values of ≤2 μg/ml and at 24 h intervals following the PO route for bacteria with MIC value of ≤0.75 μg/ml. However, further studies are needed to determine in vitro and in vivo antibacterial efficacy and multiple dosage regimens of cefquinome against pathogens isolated from rainbow trout.

Disposition of Cefquinome in Turkeys (Meleagris gallopavo) Following Intravenous and Intramuscular Administration

The bioavailability and pharmacokinetics in turkeys of cefquinome (CFQ), a broad-spectrum 4th-generation cephalosporin antibiotic, were explored after a single injection of 2 mg/kg body weight by intravenous (IV) and intramuscular (IM) routes. In a crossover design and 3-weeks washout interval, seven turkeys were assigned for this objective. Blood samples were collected prior to and at various time intervals following each administration. The concentration of CFQ in plasma was measured using HPLC with a UV detector set at 266 nm. For pharmacokinetic analysis, non-compartmental methods have been applied. Following IV administration, the elimination half-life (t_1/2ʎz), distribution volume at steady state (Vd_ss), and total body clearance (Cl_tot) of CFQ were 1.55 h, 0.54 L/kg, and 0.32 L/h/kg, respectively. Following the IM administration, CFQ was speedily absorbed with an absorption half-life (t_1/2ab) of 0.25 h, a maximum plasma concentration (C_max) of 2.71 μg/mL, attained (T_max) at 0.56 h. The bioavailability (F) and in vitro plasma protein binding of CFQ were 95.56% and 11.5%, respectively. Results indicated that CFQ was speedily absorbed with a considerable bioavailability after IM administration. In conclusion, CFQ has a favorable disposition in turkeys that can guide to estimate optimum dosage regimes and eventually lead to its usage to eradicate turkey's susceptible bacterial infections.

Temperature-dependent pharmacokinetics of trichlorfon in common carp (Cyprinus carpio L.) after bath immersion therapy

The common carp (Cyprinus carpio L.) is one of the most important freshwater fish species. As C. carpio culture has escalated, bacterial and parasitic infections have become a real threat to the industry. Antibacterial and antiparasitic treatments are provided for infection control in C. carpio. However, adequate vaccines have not yet been developed. Trichlorfon (TCF), an organophosphate, is an antiparasitic agent used in aquaculture to treat external parasites. However, there are few pharmacokinetic (PK) studies on its use in fish. This study investigated the residue elimination and temperature-dependent PK characteristics of TCF in C. carpio at 15°C and 25°C after 30 mg/L TCF bath immersion for 30 min. TCF residue concentrations in plasma and muscle tissues were determined using liquid chromatography-tandem mass spectrometry and further analyzed using a noncompartmental model. Temperature significantly affected specific PK parameters. Increasing the temperature from 15°C to 25°C shortened the elimination half-life from 36.07 to 22.72 h. The time to reach the maximum plasma TCF residue concentration (C_max ) (T_max ) remained the same (0.5 h), but C_max increased from 67.72 to 70.76 µg/L. The area under the plasma concentration-time curve decreased from 1,057.31 to 962.14 h∙µg/L. The muscle TCF C_max was 446.99 µg/L with a corresponding T_max of 0.5 h at 25°C, and 267.53 µg/L, with a corresponding T_max of 1.0 h at 15°C. The temperature-sensitive PK parameters, such as increased in C_max and decreased elimination and distribution rates, significantly affected the plasma TCF residue concentration and its overall exposure to increasing temperature. Temperature affected the therapeutic outcomes of TCF treatment in C. carpio and likely other freshwater fish. Therefore, proper dosing regimens should take temperature into consideration.

Computational Approaches in Preclinical Studies on Drug Discovery and Development

Because undesirable pharmacokinetics and toxicity are significant reasons for the failure of drug development in the costly late stage, it has been widely recognized that drug ADMET properties should be considered as early as possible to reduce failure rates in the clinical phase of drug discovery. Concurrently, drug recalls have become increasingly common in recent years, prompting pharmaceutical companies to increase attention toward the safety evaluation of preclinical drugs. In vitro and in vivo drug evaluation techniques are currently more mature in preclinical applications, but these technologies are costly. In recent years, with the rapid development of computer science, in silico technology has been widely used to evaluate the relevant properties of drugs in the preclinical stage and has produced many software programs and in silico models, further promoting the study of ADMET in vitro. In this review, we first introduce the two ADMET prediction categories (molecular modeling and data modeling). Then, we perform a systematic classification and description of the databases and software commonly used for ADMET prediction. We focus on some widely studied ADMT properties as well as PBPK simulation, and we list some applications that are related to the prediction categories and web tools. Finally, we discuss challenges and limitations in the preclinical area and propose some suggestions and prospects for the future.